ES2152252T3 - Indolocarbazolimidas y su empleo. - Google Patents

Indolocarbazolimidas y su empleo.

Info

Publication number
ES2152252T3
ES2152252T3 ES93912820T ES93912820T ES2152252T3 ES 2152252 T3 ES2152252 T3 ES 2152252T3 ES 93912820 T ES93912820 T ES 93912820T ES 93912820 T ES93912820 T ES 93912820T ES 2152252 T3 ES2152252 T3 ES 2152252T3
Authority
ES
Spain
Prior art keywords
diseases
well
cardiac
indolocarbazolimidas
employment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93912820T
Other languages
English (en)
Inventor
Jurgen Kleinschroth
Christoph Schachtele
Johannes Hartenstein
Claus Rudolph
Hubert Barth
Julian Aranda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KTB Tumorforschungs GmbH
Original Assignee
KTB Tumorforschungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KTB Tumorforschungs GmbH filed Critical KTB Tumorforschungs GmbH
Application granted granted Critical
Publication of ES2152252T3 publication Critical patent/ES2152252T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL OBJETIVO DE LA INVENCION ES EL COMPUESTO DE IMIDAS INDOLO CARBAZOL DE LA FORMULA GENERAL (I) PARA LA ELABORACION DE MEDICAMENTOS EN EL TRATAMIENTO Y/O PREVENCION DEL CANCER, ENFERMEDADES VIRALES (P. EJ. INFECCIONES HIV), ENFERMEDADES CARDIACAS Y CIRCULATORIAS (COMO P.EJ. HIPERTENSION, TROMBOSIS, IRREGULARIDADES DEL RITMO CARDIACO, ATEROSCLEROSIS), ENFERMEDADES BRONCOPULMONARES, ENFERMEDADES DEGENERATIVAS DEL SISTEMA NERVIOSO CENTRAL (P.EJ. ENFERMEDAD DE ALZHEIMER), ENFERMEDADES INFLAMATORIAS (P.EJ. REUMA, ARTRITIS), ENFERMEDADES DEL SISTEMA INMUNOLOGICO (P. EJ. ALERGIAS), ASI COMO PSORIASIS O SU UTILIZACION COMO INMUNOSUPRESIVO ASI COMO NUEVOS COMPUESTOS DE LA FORMULA (I).
ES93912820T 1992-05-30 1993-05-28 Indolocarbazolimidas y su empleo. Expired - Lifetime ES2152252T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4217964A DE4217964A1 (de) 1992-05-30 1992-05-30 Indolocarbazol-Imide und deren Verwendung

Publications (1)

Publication Number Publication Date
ES2152252T3 true ES2152252T3 (es) 2001-02-01

Family

ID=6460104

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93912820T Expired - Lifetime ES2152252T3 (es) 1992-05-30 1993-05-28 Indolocarbazolimidas y su empleo.

Country Status (18)

Country Link
US (2) US5883114A (es)
EP (1) EP0642513B1 (es)
JP (2) JP3587522B2 (es)
KR (1) KR950701811A (es)
AT (1) ATE195315T1 (es)
AU (1) AU687350B2 (es)
CA (1) CA2135768C (es)
CZ (1) CZ295394A3 (es)
DE (2) DE4217964A1 (es)
DK (1) DK0642513T3 (es)
ES (1) ES2152252T3 (es)
FI (1) FI945625L (es)
HU (1) HUT71102A (es)
NO (1) NO302574B1 (es)
NZ (1) NZ253090A (es)
RU (1) RU2126007C1 (es)
SK (1) SK146394A3 (es)
WO (1) WO1993024491A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE69327153T2 (de) * 1992-09-02 2000-05-25 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv-medikament
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
ES2123873T3 (es) * 1994-08-04 1999-01-16 Hoffmann La Roche Pirrolocarbazol.
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
PE91698A1 (es) * 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91498A1 (es) * 1996-07-29 1998-12-22 Hoffmann La Roche Pirroles sustituidos
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
US6281356B1 (en) * 1999-12-22 2001-08-28 Hoffmann-La Roche Inc. Substituted pyrroles
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
ES2189597B2 (es) * 2000-07-18 2004-06-16 Fundacion Universitaria San Pablo-Ceu Derivados de 12,13-dihidro-5h-indolo(2,3-a)pirrolo(3,4-c)carbazol-5,7(6h)-diona como agentes antineoplasicos.
DK1325011T3 (da) 2000-09-29 2004-08-16 Lilly Co Eli Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
KR100446090B1 (ko) * 2000-10-19 2004-08-30 주식회사 엘컴사이언스 사우로락탐계 알카로이드의 퇴행성 뇌신경계 질환의 예방과 치료제로서의 용도 및 이 화합물을 유효성분으로 함유하는 약학적 제제
ATE315335T1 (de) 2000-10-31 2006-02-15 Advanced Life Sciences Inc Indolocarbazol-antikrebsmittel und verfahren zu ihrer verwendung
US7122526B2 (en) * 2000-10-31 2006-10-17 Nanosphere, Inc. Indolocarbazole anticancer agents and methods of using same
SG159378A1 (en) * 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
EP1390029B1 (en) 2001-04-11 2009-12-16 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
WO2003022861A1 (en) * 2001-09-13 2003-03-20 Bristol-Myers Squibb Company Process for the preparation of rebeccamycin and analogs thereof
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
FR2833840B1 (fr) * 2001-12-21 2010-06-18 Rytek Methodes et compositions pour le traitement de pathologies respiratoires
JP2006500355A (ja) * 2002-08-07 2006-01-05 イデニクス（ケイマン）リミテツド Ｈｉｖ治療用の置換フェニルインドール類
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
DE602005011031D1 (en) * 2004-09-17 2008-12-24 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
FR2879100B1 (fr) * 2004-12-09 2007-07-06 Lionel Bueno Compositions pour le traitement des pathologies oculaires de surface et de la retine
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
EP2047849A1 (en) * 2007-10-08 2009-04-15 KTB Tumorforschungsgesellschaft mbH Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors
EP3741375A1 (en) 2014-07-17 2020-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
CN107556323B (zh) * 2017-08-30 2019-09-20 浙江大学 一种氨基取代星孢菌素类化合物及其制备方法和应用
US11319320B2 (en) * 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
CN113980000B (zh) * 2021-12-30 2022-05-20 北京鑫开元医药科技有限公司 甲基酮类衍生物、制备方法、药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217885A (en) * 1989-03-23 1993-06-08 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C
JP3010675B2 (ja) * 1989-03-23 2000-02-21 萬有製薬株式会社 抗腫瘍性物質ｂｅ―１３７９３ｃ
EP0528030B1 (en) * 1990-05-11 1997-09-17 Banyu Pharmaceutical Co., Ltd. Antitumor be-13793c derivative
CA2130836A1 (en) * 1992-03-20 1993-09-30 Martin J. Slater Further indole derivatives with antiviral activity

Also Published As

Publication number Publication date
ATE195315T1 (de) 2000-08-15
FI945625A7 (fi) 1994-11-29
EP0642513B1 (de) 2000-08-09
CA2135768A1 (en) 1993-12-01
US5883114A (en) 1999-03-16
CZ295394A3 (en) 1995-03-15
RU2126007C1 (ru) 1999-02-10
HUT71102A (en) 1995-11-28
FI945625A0 (fi) 1994-11-29
JPH07508268A (ja) 1995-09-14
NO302574B1 (no) 1998-03-23
NZ253090A (en) 1997-02-24
FI945625L (fi) 1994-11-29
AU4319493A (en) 1993-12-30
AU687350B2 (en) 1998-02-26
SK146394A3 (en) 1995-08-09
HU9403419D0 (en) 1995-02-28
JP3587522B2 (ja) 2004-11-10
NO944564L (no) 1995-01-30
KR950701811A (ko) 1995-05-17
DK0642513T3 (da) 2001-01-02
DE4217964A1 (de) 1993-12-02
RU94046306A (ru) 1996-10-27
WO1993024491A1 (de) 1993-12-09
US5945440A (en) 1999-08-31
CA2135768C (en) 2004-11-23
NO944564D0 (no) 1994-11-29
DE59310085D1 (de) 2000-09-14
EP0642513A1 (de) 1995-03-15
JP2004026842A (ja) 2004-01-29

Similar Documents

Publication Publication Date Title
DE59310085D1 (de) Indolocarbazol-imide und deren verwendung
FI902251A0 (fi) Maleinimidderivat och deras anvaendning som laekemedel.
EA200200249A1 (ru) Производные 3(5)-уреидопиразола, способ их получения и их применение в качестве противоопухолевых агентов
EP1634881A4 (en) HARMINIC DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, METHODS OF PREPARATION, AND USE OF SUCH DERIVATIVES
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ES2169127T3 (es) Nuevos carbamatos y ureas como modificadores de la resistencia multi-farmaco.
NO178969C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte kinazolinoner
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
IS6491A (is) Pteridínefnasambönd til meðhöndlunar á sóríasis
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
EP1353672A4 (en) Synthesis of 3-amino-thalidomide and its enantiomers
ATE384068T1 (de) Thiazolo(4,5-d)pyrimidinverbindungen zur behandlung von rheumathoider arthritis
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
ES2111617T3 (es) Derivados de pirimidina condensados y su utilizacion como antagonistas de la angiotensina ii.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
ES2153862T3 (es) Bisulfan de administracion parenteral para el tratamiento de enfermedades malignas.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DK0434057T3 (da) Indocarbazol-derivater, fremgangsmåder til deres fremstilling og deres anvendelse
RU94043771A (ru) Замещенные бензимидазольные соединения, способ лечения, фармацевтическая композиция и способ получения бензимидазольных соединений
BG102080A (en) Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists
MX9403032A (es) Quinolil-dihidropiridinas condensadas, procedimiento para su fabricacion ysu uso en medicamentos.
PT919544E (pt) Compostos uteis para o tratamento de alergias e doencas unflamatorias
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
CU22713A3 (es) Procedimiento de obtencion del compuesto 4-(2-cloro-3-ciano-fenil)-1,4-dihidro-2,6-dimetilpiridin-3,5-dicarboxilato de isopropilo y 2-metoxietilo
ES2088162T3 (es) Tienopirazina-2,3-dionas utiles para el tratamiento de enfermedades del sistema nervioso central, y su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 642513

Country of ref document: ES